Medicus Pharma (NASDAQ:MDCX – Get Free Report) and Vanda Pharmaceuticals (NASDAQ:VNDA – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, valuation, profitability, analyst recommendations, institutional ownership and dividends.
Analyst Recommendations
This is a breakdown of current ratings and target prices for Medicus Pharma and Vanda Pharmaceuticals, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Medicus Pharma | 1 | 1 | 2 | 0 | 2.25 |
| Vanda Pharmaceuticals | 1 | 2 | 5 | 0 | 2.50 |
Medicus Pharma presently has a consensus target price of $9.00, suggesting a potential upside of 2,900.00%. Vanda Pharmaceuticals has a consensus target price of $14.30, suggesting a potential upside of 131.02%. Given Medicus Pharma’s higher possible upside, research analysts plainly believe Medicus Pharma is more favorable than Vanda Pharmaceuticals.
Valuation & Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Medicus Pharma | N/A | N/A | -$35.46 million | ($2.68) | -0.11 |
| Vanda Pharmaceuticals | $216.10 million | 1.72 | -$220.47 million | ($4.05) | -1.53 |
Medicus Pharma has higher earnings, but lower revenue than Vanda Pharmaceuticals. Vanda Pharmaceuticals is trading at a lower price-to-earnings ratio than Medicus Pharma, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
88.1% of Vanda Pharmaceuticals shares are owned by institutional investors. 8.1% of Medicus Pharma shares are owned by company insiders. Comparatively, 10.0% of Vanda Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Volatility and Risk
Medicus Pharma has a beta of -0.47, suggesting that its stock price is 147% less volatile than the S&P 500. Comparatively, Vanda Pharmaceuticals has a beta of 0.65, suggesting that its stock price is 35% less volatile than the S&P 500.
Profitability
This table compares Medicus Pharma and Vanda Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Medicus Pharma | N/A | -3,137.84% | -311.33% |
| Vanda Pharmaceuticals | -109.99% | -32.26% | -23.43% |
Summary
Vanda Pharmaceuticals beats Medicus Pharma on 8 of the 13 factors compared between the two stocks.
About Medicus Pharma
Medicus Pharma Ltd is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. Medicus Pharma Ltd is based in Toronto, Ontario.
About Vanda Pharmaceuticals
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson’s disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company’s pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.
Receive News & Ratings for Medicus Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicus Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
